litlas
ログインアカウント作成

John M. Pagel

1994–2025 年に発表

102
論文数
20,075
被引用数
57
h 指数
100
i10 指数

被引用数

John M. Pagel の年別被引用数1994 年: 被引用 15 件1995 年: 被引用 25 件1996 年: 被引用 25 件1997 年: 被引用 30 件1998 年: 被引用 39 件1999 年: 被引用 35 件2000 年: 被引用 22 件2001 年: 被引用 34 件2002 年: 被引用 14 件2003 年: 被引用 15 件2004 年: 被引用 4 件2005 年: 被引用 8 件2006 年: 被引用 11 件2007 年: 被引用 15 件2008 年: 被引用 18 件2009 年: 被引用 24 件2010 年: 被引用 41 件2011 年: 被引用 39 件2012 年: 被引用 35 件2013 年: 被引用 64 件2014 年: 被引用 77 件2015 年: 被引用 135 件2016 年: 被引用 173 件2017 年: 被引用 203 件2018 年: 被引用 236 件2019 年: 被引用 601 件2020 年: 被引用 825 件2021 年: 被引用 1,123 件2022 年: 被引用 1,004 件2023 年: 被引用 733 件2024 年: 被引用 1,165 件2025 年: 被引用 519 件2026 年: 被引用 6 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,790 件、この内訳の 29.5%中国: 引用元論文 692 件、この内訳の 7.3%ドイツ: 引用元論文 647 件、この内訳の 6.9%イギリス: 引用元論文 614 件、この内訳の 6.5%イタリア: 引用元論文 521 件、この内訳の 5.5%フランス: 引用元論文 412 件、この内訳の 4.4%オーストラリア: 引用元論文 395 件、この内訳の 4.2%スペイン: 引用元論文 330 件、この内訳の 3.5%オランダ: 引用元論文 263 件、この内訳の 2.8%カナダ: 引用元論文 252 件、この内訳の 2.7%スイス: 引用元論文 198 件、この内訳の 2.1%スウェーデン: 引用元論文 174 件、この内訳の 1.8%
0%29.5%その他 22.8%

機関

分野

  • Medicine80.5%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology2.8%
  • Chemistry0.4%
  • Engineering0.4%
  • Computer Science0.3%
  • その他1.2%

トピック

  • CAR-T cell therapy research12.8%
  • Chronic Lymphocytic Leukemia Research10.1%
  • Lymphoma Diagnosis and Treatment8.7%
  • Acute Myeloid Leukemia Research3.7%
  • Immune Cell Function and Interaction3%
  • Virus-based gene therapy research2.9%
  • その他58.8%

共著者

全論文

検索で開く
  1. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    著者: Frederick L. Locke, David B. Miklos, Caron A. Jacobson, Miguel‐Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin - New England Journal of Medicine 2021 被引用: 1,520

  2. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    著者: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 被引用: 1,823

  3. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    著者: Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour - New England Journal of Medicine 2015 被引用: 1,884

  4. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    著者: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 被引用: 318

  5. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    著者: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd - The Lancet 2020 被引用: 612

  6. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    著者: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 被引用: 454

  7. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

    著者: Bijal Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda - Blood 2021 被引用: 200

  8. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    著者: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd - Leukemia 2022 被引用: 200

  9. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    著者: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 被引用: 229

  10. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    著者: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 被引用: 1,684

  11. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    著者: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori A. Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod Humerickhouse, Gary Gordon, John F. Gerecitano - Journal of Clinical Oncology 2017 被引用: 751

  12. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Bonnie K. Harrington, Susan O’Brien, Jeffrey A. Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G. Wierda, Farrukh T. Awan, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J. Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G. Diacovo, Amy J. Johnson, Richard R. Furman - New England Journal of Medicine 2015 被引用: 891

  13. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

    著者: Brian G. Till, Michael C. Jensen, Jinjuan Wang, Eric Chen, Brent L. Wood, Harvey A. Greisman, Xiaojun Qian, Scott E. James, Andrew Raubitschek, Stephen J. Forman, Ajay K. Gopal, John M. Pagel, Catherine Lindgren, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press - Blood 2008 被引用: 719

  14. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

    著者: Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal, David G. Maloney, Catherine Lindgren, Yukang Lin, John M. Pagel, Lihua E. Budde, Andrew Raubitschek, Stephen J. Forman, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press - Blood 2012 被引用: 530

  15. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

    著者: Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer A. Woyach, Елена Бибикова, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd - Blood Advances 2019 被引用: 185

  16. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    著者: Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer - Journal of Clinical Oncology 2019 被引用: 221

  17. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

    著者: John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen A. Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman - Blood 2019 被引用: 178

  18. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

    著者: Roland B. Walter, Sarah Buckley, John M. Pagel, Brent L. Wood, Barry E. Storer, Brenda M. Sandmaier, Min Fang, Boglarka Gyurkocza, Colleen Delaney, Jerald P. Radich, Elihu H. Estey, Frederick R. Appelbaum - Blood 2013 被引用: 357

  19. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

    著者: John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown - Blood 2019 被引用: 243

  20. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

    著者: Jason R. Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B. Miklos, Matthew L. Ulrickson, Miguel‐Angel Perales, Umar Farooq, Luciano Wannesson, Lori A. Leslie, Marie José Kersten, Caron A. Jacobson, John M. Pagel, Gerald Wulf, Patrick B. Johnston, Aaron P. Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia Thornton Snider, Paul Cheng, Christina To, Olalekan O. Oluwole, Anna Sureda - Clinical Cancer Research 2023 被引用: 47

  21. Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

    著者: Roland B. Walter, Ted Gooley, Brent L. Wood, Filippo Milano, Min Fang, Mohamed L. Sorror, Elihu H. Estey, Alexander I. Salter, Emily Lansverk, Jason W. Chien, Ajay K. Gopal, Frederick R. Appelbaum, John M. Pagel - Journal of Clinical Oncology 2011 被引用: 399

  22. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

    著者: Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopińska‐Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech‐Marańda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chávez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O’Connor, Michael Weiss, Pier Luigi Zinzani - Journal of Clinical Oncology 2021 被引用: 161

  23. Acalabrutinib in treatment-naive chronic lymphocytic leukemia

    著者: John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda - Blood 2021 被引用: 98

  24. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

    著者: Guillermo Garcia‐Manero, Nikolai A. Podoltsev, Megan Othus, John M. Pagel, Jerald P. Radich, Min Fang, David A. Rizzieri, Guido Marcucci, Stephen A. Strickland, Mark R. Litzow, Mary Lynn Savoie, Bruno C. Medeiros, Mikkael A. Sekeres, Tara L. Lin, Geoffrey L. Uy, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Richard M. Stone, David F. Claxton, James Essell, Selina M. Luger, Sanjay Mohan, Anna Moseley, Frederick R. Appelbaum, Harry P. Erba - Leukemia 2023 被引用: 32